Skip to Main Content

Key Features

  • Hepatitis D virus (HDV) causes hepatitis only in the presence of hepatitis B surface antigen (HBsAg); it is cleared when the latter is cleared

  • May coinfect with hepatitis B virus (HBV) or may superinfect a person with chronic hepatitis B, usually by percutaneous exposure

  • Patients with long-standing chronic hepatitis D and B often have inactive cirrhosis and are at risk for decompensation and hepatocellular carcinoma

  • Three-fold increased risk of hepatocellular carcinoma

Clinical Findings

  • When acute hepatitis D is coincident with acute HBV infection, the infection is generally similar in severity to acute hepatitis B alone

  • In chronic hepatitis B, superinfection by HDV appears to carry a worse short-term prognosis, often resulting in acute liver failure or severe chronic hepatitis that progresses rapidly to cirrhosis


  • Made by detecting antibodies to hepatitis D antigen (anti-HDV) or, where available, hepatitis D antigen (HDAg) or HDV RNA in serum


  • Peginterferon alfa-2b (1.5 mcg/kg/wk for 48 weeks) may lead to normalization of serum aminotransferase levels, histologic improvement, and elimination of HDV RNA from serum in 20–50% of patients with chronic hepatitis D

  • However, relapse may occur and tolerance is poor

  • Nucleoside and nucleotide analogs are not effective in treating chronic hepatitis D

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.